Septic patients often die in a context of multiple organ dysfunction syndrome (MODS), despite the macro-hemodynamic parameters being normalized and after the onset of antibiotic therapy. Microcirculation injury during sepsis affects capillary permeability and leukocyte–endothelium interactions and is thought to be instrumental in organ injury. Several studies have demonstrated a beneficial effect of mesenchymal stromal cells (MSCs) injection on survival and organ dysfunctions in sepsis models. In vivo activity of MSCs also appears to be very much dependent on the information provided before injection. Indeed preconditioning by interferon γ (IFNγ; MSC-IFNγ) increases immunosuppressive capacity of MSCs in vitro and in vivo. Therefore, the objective was to evaluate the effect of MSC naive or IFNγ preconditioned on leukocyte–endothelium interactions in a polymicrobial sepsis model by intraperitoneal feces injection. Six hours (H6) after this induction, we used intravital microscopy in mice cremaster muscle venules to study the flow behavior of leukocytes. Plasmas were harvested to evaluate inflammation level and endothelial activation. We showed that MSC-IFNγ have a beneficial effect on microcirculation, by increasing the flow of white blood cells (WBCs) and the percentage of venules containing flowing WBCs, by significantly reducing the adhesion of WBCs and by increasing the average red blood cell velocity (VRBC). In conclusion, our results suggest that intravenous injection of preconditioned MSC-IFNγ improves microvascular hemodynamics in early phases of sepsis.
Get full access to this article
View all access options for this article.
References
1.
SingerM, DeutschmanCS, SeymourCW, Shankar-HariM, AnnaneD, BauerM, BellomoR, BernardGR, ChicheJD, et al. (2016). The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 315:801–810.
2.
De BackerD, Orbegozo CortesD, DonadelloK and VincentJL. (2014). Pathophysiology of microcirculatory dysfunction and the pathogenesis of septic shock. Virulence, 5:73–79.
3.
GraetzTJ and HotchkissRS. (2017). Preventing organ failure in sepsis - the search continues. Nat Rev Nephrol, 13:5–6.
4.
SakrY, DuboisMJ, De BackerD, CreteurJ and VincentJL. (2004). Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Critic Care Med, 32:1825–1831.
5.
De BackerD, DonadelloK, SakrY, Ospina-TasconG, SalgadoD, ScollettaS and VincentJL. (2013). Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome. Crit Care Med, 41:791–799.
6.
NakagawaNK, JukemuraJ, AikawaP, NogueiraRA, Poli-de-FigueiredoLF and SannomiyaP. (2007). In vivo observation of mesenteric leukocyte-endothelial interactions after cecal ligation/puncture and surgical sepsis source control. Clinics (Sao Paulo), 62:321–326.
7.
NakajimaY, BaudryN, DuranteauJ and VicautE. (2006). Effects of vasopressin, norepinephrine, and L-arginine on intestinal microcirculation in endotoxemia. Crit Care Med, 34:1752–1757.
8.
IskitAB, SungurA, GedikogluG and GucMO. (1999). The effects of bosentan, aminoguanidine and L-canavanine on mesenteric blood flow, spleen and liver in endotoxaemic mice. Eur J Pharmacol, 379:73–80.
9.
KusadasiN and GroeneveldAB. (2013). A perspective on mesenchymal stromal cell transplantation in the treatment of sepsis. Shock, 40:352–357.
10.
NemethK, LeelahavanichkulA, YuenPS, MayerB, ParmeleeA, DoiK, RobeyPG, LeelahavanichkulK, KollerBH, et al. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med, 15:42–49.
11.
MeiSH, HaitsmaJJ, Dos SantosCC, DengY, LaiPF, SlutskyAS, LilesWC and StewartDJ. (2010). Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med, 182:1047–1057.
12.
WeilBR, ManukyanMC, HerrmannJL, WangY, AbarbanellAM, PoynterJA and MeldrumDR. (2010). Mesenchymal stem cells attenuate myocardial functional depression and reduce systemic and myocardial inflammation during endotoxemia. Surgery, 148:444–452.
13.
WeilBR, HerrmannJL, AbarbanellAM, ManukyanMC, PoynterJA and MeldrumDR. (2011). Intravenous infusion of mesenchymal stem cells is associated with improved myocardial function during endotoxemia. Shock, 36:235–241.
14.
PolchertD, SobinskyJ, DouglasG, KiddM, MoadsiriA, ReinaE, GenrichK, MehrotraS, SettyS, SmithB and BartholomewA. (2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol, 38:1745–1755.
15.
RyanJM, BarryF, MurphyJM and MahonBP. (2007). Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol, 149:353–363.
16.
BaudryN, LaemmelE and VicautE. (2008). In vivo reactive oxygen species production induced by ischemia in muscle arterioles of mice: involvement of xanthine oxidase and mitochondria. Am J Physiol Heart Circ Physiol, 294:H821–H828.
17.
BaudryN, DanialouG, BoczkowskiJ and VicautE. (1998). In vivo study of the effect of systemic hypoxia on leukocyte-endothelium interactions. Am J Respir Crit Care Med, 158:477–483.
18.
HallSR, TsoyiK, IthB, PaderaRF Jr., LedererJA, WangZ, LiuX and PerrellaMA. (2013). Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils. Stem Cells, 31:397–407.
19.
KrasnodembskayaA, SamaraniG, SongY, ZhuoH, SuX, LeeJW, GuptaN, PetriniM and MatthayMA. (2012). Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol, 302:L1003–L1013.
20.
BurasJA, HolzmannB and SitkovskyM. (2005). Animal models of sepsis: setting the stage. Nat Rev Drug Discov, 4:854–865.
21.
LaroyeC, GibotS, ReppelL and BensoussanD. (2017). Concise Review: mesenchymal Stromal/Stem Cells: a New Treatment for Sepsis and Septic Shock?. Stem Cells, 35:2331–2339.
22.
Le BurelS, ThepenierC, BoutinL, LatailladeJJ and PeltzerJ. (2017). Effect of Mesenchymal Stromal Cells on T Cells in a Septic Context: immunosuppression or Immunostimulation?. Stem Cells Dev, 26:1477–1489.
23.
LiJ, EzzelarabMB and CooperDK. (2012). Do mesenchymal stem cells function across species barriers? Relevance for xenotransplantation. Xenotransplantation, 19:273–285.
24.
SchweizerR, KamatP, SchweizerD, DennlerC, ZhangS, SchniderJT, SalemiS, GiovanoliP, EberliD, et al. (2014). Bone marrow-derived mesenchymal stromal cells improve vascular regeneration and reduce leukocyte-endothelium activation in critical ischemic murine skin in a dose-dependent manner. Cytotherapy, 16:1345–1360.
25.
KavanaghDP, SureshS, NewsomePN, FramptonJ and KaliaN. (2015). Pretreatment of mesenchymal stem cells manipulates their vasculoprotective potential while not altering their homing within the injured gut. Stem Cells, 33:2785–2797.
26.
FerriLE, PascualJ, SeelyAJ, GianniasB and ChristouNV. (2004). Intra-abdominal sepsis attenuates local inflammation-mediated increases in microvascular permeability at remote sites in mice in vivo. Surgery, 135:187–195.
27.
SwartzDE, SeelyAJ, FerriL, GianniasB and ChristouNV. (2000). Decreased systemic polymorphonuclear neutrophil (PMN) rolling without increased PMN adhesion in peritonitis at remote sites. Arch Surg, 135:959–966.
28.
HickeyMJ, SharkeyKA, SihotaEG, ReinhardtPH, MacmickingJD, NathanC and KubesP. (1997). Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. FASEB J, 11:955–964.
29.
GrundlingM, RickertS, SaegerD, PavlovicD, UsichenkoT, MeissnerK, WendtM, HungO, MurphyM, WhynotS and LehmannC. (2009). Acute high-dose sodium selenite administration improves intestinal microcirculation without affecting cytokine release in experimental endotoxemia. J Trace Elem Med Biol, 23:138–143.
30.
PiperRD, Pitt-HydeML, AndersonLA, SibbaldWJ and PotterRF. (1998). Leukocyte activation and flow behavior in rat skeletal muscle in sepsis. Am J Respir Crit Care Med, 157:129–134.
31.
PaulusP, JenneweinC and ZacharowskiK. (2011). Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?. Biomarkers, 16(Suppl 1):S11–S21.
32.
KimJY, KimDH, KimJH, LeeD, JeonHB, KwonSJ, KimSM, YooYJ, LeeEH, et al. (2012). Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-beta plaques. Cell Death Differ, 19:680–691.
33.
PeltzerJ, MontespanF, ThepenierC, BoutinL, UzanG, Rouas-FreissN and LatailladeJJ. (2015). Heterogeneous functions of perinatal mesenchymal stromal cells require a preselection before their banking for clinical use. Stem Cells Dev, 24:329–344.
34.
AndreevaE, BobylevaP, GornostaevaA and BuravkovaL. (2017). Interaction of multipotent mesenchymal stromal and immune cells: bidirectional effects. Cytotherapy, 19:1152–1166.
35.
RenG, ZhaoX, ZhangL, ZhangJ, L'HuillierA, LingW, RobertsAI, LeAD, ShiS, ShaoC and ShiY. (2010). Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol, 184:2321–2328.
36.
BoldtJ, MullerM, KuhnD, LinkeLC and HempelmannG. (1996). Circulating adhesion molecules in the critically ill: a comparison between trauma and sepsis patients. Intensive Care Med, 22:122–128.
37.
MunirH, LuuNT, ClarkeLS, NashGB and McGettrickHM. (2016). Comparative ability of mesenchymal stromal cells from different tissues to limit neutrophil recruitment to inflamed endothelium. PLoS One, 11:e0155161.
38.
AndreevaER, UdartsevaOO, ZhidkovaOV, BuravkovSV, EzdakovaMI and BuravkovaLB. (2018). IFN-gamma priming of adipose-derived stromal cells at “physiological” hypoxia. J Cell Physiol, 233:1535–1547.
39.
DriesDJ, JurkovichGJ, MaierRV, ClemmerTP, StruveSN, WeigeltJA, StanfordGG, HerrDL, ChampionHR, et al. (1994). Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. Arch Surg, 129:1031–1041; discussion 1042.
40.
SchrepferS, DeuseT, ReichenspurnerH, FischbeinMP, RobbinsRC and PelletierMP. (2007). Stem cell transplantation: the lung barrier. Transplant Proc, 39:573–576.
41.
CesarzZ and TamamaK. (2016). Spheroid culture of mesenchymal stem cells. Stem Cells Int, 2016:9176357.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
